OBJECTIVES Pharmaceutical supply chain is a significant component of the health system in supplying medicines, particularly in countries where main drugs are provided by local pharmaceutical companies. No previous studies exist assessing risks and disruptions in pharmaceutical companies while assessing the pharmaceutical supply chain. Any risks affecting the pharmaceutical companies could disru...

The pharmaceutical industry raises unique economic questions because of three related features. First, the high rate of R&D, technical change and importance of patent protection raise important positive and normative questions related to industry structure, prices, profits and public policy. Second, the industry is heavily regulated in all major functions. Early regulatory requirements focused ...

The pharmaceutical industry has been receiving greater scrutiny lately due in large part to the many public and private legal enforcement actions taken against pharmaceutical manufacturers. These enforcement actions, along with legal developments such as the OIG Compliance Guidance for Pharmaceutical Manufacturers, the Sarbanes-Oxley Act's statutory guidelines for public corporations, the HIPAA...

1. Distribute a full line of pharmaceutical products and health and beauty aids to chain stores, independent drug stores, hospitals, and other health care facilities. In other words, FoxMeyer’s customers were retailers and dispensers. 2. Provide managed care and information-based services to health care facilities, pharmacies and physicians. 3. Conduct business in franchising variety stores and...

In this paper we explore the impact of electronic commerce on the industry structure and market power allocation of China’s pharmaceutical industry. Firstly, we describe the overall characteristics of the pharmaceutical Industry in general. Secondly, we develop a value chain based framework of analysis for China’s pharmaceutical industry. We divide the pharmaceutical industry value chain into t...

INTRODUCTION Policy-makers worldwide struggle to balance health with industrial policy objectives in the pharmaceutical sector. Tensions arise over pricing and reimbursement in particular. What health plans view as necessary to maintain equitable access to medicines, industry views as inimical to R&D and innovation. Australia has grappled with this issue for years, even incorporating the goal o...